Skip to content
WorldBrand.AI
HomeAboutBrand WikiAEOWorld ModelComing SoonBlog
WorldBrand.AI

The intelligence platform for brands in the AI era.

Products
  • AEO Intelligence
  • Brand Wiki
  • World Model
  • Enterprise
Company
  • About
  • Blog
  • Pricing
Brand Wiki
  • About Brand Wiki
  • Methodology
  • Sources
  • Editorial policy
  • API

© 2026 WorldBrand.ai. All rights reserved.

Privacy PolicyTerms of Use

Amgen/Controversies

Amgen controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile

  1. 2026France recalls Tavneos batches after deaths linked in Japan
  2. 2012Off-label promotion, kickbacks, and pricing settlement

  1. 2026

    France recalls Tavneos batches after deaths linked in Japan

    Recall announced

    France's medicine safety agency ANSM said the recall of all Tavneos batches available in France would begin on August 19, after the drug, made by U.S. biotech firm Amgen and sold by partner companies worldwide, was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.

    Company response

    • Recall — France's medicine safety agency ANSM

      "The recall of all batches available in France will begin on August 19," France's medicine safety agency ANSM said in a statement.

    Source excerpt

    • A drug called Tavneos used to treat rare autoimmune diseases will be pulled from the shelves in France, the country's medicine watchdog said Wednesday, after it was linked to 20 deaths in Japan.
    • "The recall of all batches available in France will begin on August 19," France's medicine safety agency ANSM said in a statement.
    • Tavneos is made by the U.S. biotech firm Amgen and is sold by different partner pharmaceutical companies around the world.
    Source

  2. 2012

    Off-label promotion, kickbacks, and pricing settlement

    Amgen pleaded guilty to a federal charge and paid $762 million to resolve criminal and civil allegations concerning promotion of medicines for unapproved uses, improper inducements, and false pricing submissions.

    Source